OBJECTIVES: Validation studies of European system for cardiac operative risk evaluation II (EuroSCORE II) have been limited to European datasets. Therefore, the aims of this study were to assess the performance of EuroSCORE II in a large multicentre US database, and compare it with the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM). In addition, implications for patient selection for transcatheter aortic valve implantation (TAVI) were explored.
INTRODUCTION
Risk models are essential for clinical decision-making, benchmarking of clinical practices and patient selection in clinical trials.
Several scores are currently used in cardiac surgery [1] . The widely utilized European system for cardiac operative risk evaluation (EuroSCORE) predicts 30-day mortality after cardiac surgery [2] . It was developed in 1999 using a data set of almost 15 000 patients and updated in 2003 [2, 3] . Validation studies of EuroSCORE have shown that the score over-predicts mortality, especially in highrisk patients [4, 5] . EuroSCORE II was introduced to improve performance and increase applicability to contemporary cardiac surgery [6] . It was derived from a database of 23 000 patients who underwent cardiac surgery in 43 countries in the year 2010.
The new score seems to perform better than the original score, but validation studies have been limited to European datasets [7] [8] [9] [10] [11] [12] [13] . With increasing transatlantic research collaboration and the potential benefits of using the more parsimonious EuroSCORE II also in the USA, knowledge on the performance and comparability of this score in North American patients is essential. For instance, two major multinational trials currently investigate transcatheter aortic valve implantation (TAVI) as an alternative to surgical aortic valve replacement (AVR) in intermediate risk patients (Clinicaltrials.gov identifier: NCT01586910 and NCT01314313).
These trials use the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) for patient selection, whereas EuroSCORE is used in everyday practice in Europe. Therefore, the purpose of this study was to compare the performance of EuroSCORE II with the STS-PROM model in a large multicentre US database, and also explore implications for patient selection for TAVI.
METHODS

Study population
Clinical records of patients undergoing cardiac surgery were prospectively collected from 2003 to 2012 in the Virginia Cardiac Surgery Quality Initiative (VCSQI) database. For this study, all patients who underwent isolated coronary artery bypass grafting (CABG), isolated AVR, isolated mitral valve (MV) replacement, isolated MV repair or CABG + AVR were selected. VCSQI is a voluntary consortium of 17 cardiac surgical centres providing cardiac surgery in the Commonwealth of Virginia. The database captures 99% of all cardiac surgical procedures [14] . VCSQI members contributed data to the STS Adult Cardiac Database. Data analyses were exempt from the University of Virginia Institutional Review Board, because patients were deidentified and the fact that the data were primarily collected for non-research purposes.
Definitions and risk score calculation
Operative mortality was defined as (i) death during initial hospital stay or (ii) death within 30 days if the patient is discharged <30 days. EuroSCORE II was built using death during the initial hospital stay [6] , and therefore we performed additional analyses using that end point definition. Because the performance of EuroSCORE II was similar (discrimination) or better (calibration) using the operative mortality definition, we report all comparative analyses based on that definition. Moreover, using the same end point definition facilitates the comparison in this US cohort of patients. Patient characteristics, risk factors and other variables were collected using STS database definitions. Some definitions were not totally equivalent to the EuroSCORE definitions. Critical preoperative state was assessed combining the variables resuscitation, inotrope use, ventricular tachycardia or fibrillation and preoperative intra-aortic balloon pump for haemodynamic instability. Creatinine clearance was calculated using the Cockcroft-Gault formula [15] , and where only the mean pulmonary artery pressure was collected, we calculated the systolic pulmonary pressure using the formula reported by Kind et al. [16] . No data were available for poor mobility due to musculoskeletal dysfunction and, consequently, the EuroSCORE II risk factor 'poor mobility' was based on neurological dysfunction only [11] . The Canadian Cardiovascular Society (CCS) class was not scored for each individual patient and therefore we used the variable unstable angina as a proxy. Patients were assumed to be New York Heart Association (NYHA) class 1 if congestive heart failure was absent. Subsequently, the logistic EuroSCORE and EuroSCORE II were calculated for each patient [3, 6] , while the STS-PROM had been routinely calculated at the time of data entry in the database. Since patient risk factors and case-mix in adult cardiac surgery change dynamically over time [17, 18] , sensitivity analyses were performed to investigate whether model performance was better in more recent procedures. Based on an analysis of predicted risk and mortality profiles over time, recent cases for the sensitivity analyses were defined as procedures after 1 January 2008.
Statistical analysis
Baseline characteristics are displayed as proportions or means ± standard deviation for discrete and continuous variables, respectively. The risk models were evaluated in terms of discrimination and calibration, using the area under the receiver operator curve (AUC) and calibration plots. An AUC of 1.0 indicates perfect discriminative power, whereas 0.5 indicates no discriminative abilities. AUCs were compared using the method proposed by Hanley and McNeil [19] . Calibration represents the agreement between observed outcome and predicted outcome. The HosmerLemeshow test was not used, since it is not informative in large samples. Instead, we compared observed in-hospital mortality with expected in-hospital mortality. We constructed calibration plots of observed vs expected (O:E) mortality, displaying the trend using Friedman's super-smoother methodology on the ungrouped data [20] . In addition, we divided the cohort into 10 equally sized groups based on the ranked predicted risk.
Analyses were performed for all procedures combined, as well as per procedure. Patients who underwent AVR were also classified into low, intermediate or high operative risk, according to their predicted risk of mortality (0-4%, 4-10% and >10%, respectively). These STS-PROM cut-offs are used in ongoing TAVI vs surgical AVR trials (Clinicaltrials.gov identifiers: NCT01586910 and NCT01314313). Analyses were performed with SPSS for Windows (version 20.0.0.1; IBM, Armonk, NY, USA) and the R software (version 2.15.3).
RESULTS
Patients
Full patient characteristics are presented in Table 1 . The mean age of the population was 64.7 years and 14 622 patients (28.9%) were women. The majority (40 871) of the 50 588 patients included during the study period underwent CABG. Other procedures were isolated aortic valve replacements (AVRs, 4107 patients), combined AVR + CABG (3480) procedures, isolated MV repairs (1059 patients) and isolated MV replacements (1071 patients). The mean values of the STS-PROM, EuroSCORE II and logistic EuroSCORE were 2.7%, 3.2 and 6.9%, respectively. The overall operative mortality rate was 2.1% (1071 patients).
Overall performance of the scores Figure 1 presents the AUC of the different risk prediction models in the overall cohort of patients. The STS-PROM had better discriminatory power compared with EuroSCORE II (AUC = 0.81 vs 0.77, respectively; P < 0.001) and logistic EuroSCORE (AUC = 0.81 vs 0.78, respectively; P = 0.003). The AUC of EuroSCORE II and the logistic EuroSCORE were similar (AUC = 0.77 vs 0.78, respectively; P = 0.16).
The calibration curves of the STS-PROM, EuroSCORE II and logistic EuroSCORE are presented in Fig. 2 . All scores showed a relatively linear relationship between predicted and observed mortality. The scores were below the perfect prediction line, meaning that they over-predicted mortality. In patients with a predicted risk of mortality above approximately 5%, the STS-PROM was better calibrated than EuroSCORE II. The logistic EuroSCORE considerably over-predicted in-hospital mortality in all patients. Expressed numerically, EuroSCORE II, the STS-PROM and logistic EuroSCORE had an O:E ratio of 0.68, 0.80 and 0.32, respectively ( Table 2) .
Performance according to type of procedure
The calibration of the STS-PROM and EuroSCORE II according to the type of procedure is presented numerically in Table 2 and graphically in Fig. 3 . Isolated CABG was the most common procedure and performance of the STS-PROM and EuroSCORE II was similar to their performance in the 'all procedure' category. Both scores showed good calibration up until approximately 5% of the predicted risk of mortality; after that, the STS-PROM was better calibrated than EuroSCORE II (Fig. 3A) . Discrimination in CABG patients was better with the STS-PROM model than with EuroSCORE II (AUC = 0.81 vs 0.77, respectively; P < 0.001).
For patients who underwent AVR, the STS-PROM over-predicted mortality in almost a linear fashion. (Fig. 3B ). EuroSCORE II underpredicted in low-risk patients, while it showed over-prediction in higher risk patients. The O:E ratios according to predefined risk categories showed a similar picture ( Table 3 Both the STS-PROM and EuroSCORE II performed equivalently in patients undergoing combined AVR + CABG procedures, although EuroSCORE II was slightly better calibrated in lower risk patients (Fig. 3C) . Calibration in high-risk patient was poor in both scores. Discrimination in patients undergoing AVR + CABG was similar for both scores (AUC = 0.74 for STS-PROM vs AUC = 0.72 for EuroSCORE II; P = 0.47).
The calibration plots for MV procedures showed a sizeable amount of uncertainty ( Fig. 3D and E ). There were only 116 patients with a EuroSCORE II of >4% in the MV repair group, leading to difficulties in making inferences on higher risk patients. In low-risk patients, EuroSCORE II tended to under-predict mortality, whereas the STS-PROM tended to over-predict. Also discrimination with the STS-PROM and EuroSCORE II was similar (AUC = 0.86 vs 0.82, respectively; P = 0.55). Among patients who underwent MV replacement, 330 had a EuroSCORE of >4%, but substantial variances in O:E ratios hinder inferences on the calibration of both scores. Discrimination was similar (AUC = 0.79 for STS-PROM vs AUC = 0.78 for EuroSCORE II; P = 0.69).
Sensitivity analysis of recent cases
The sensitivity analysis showed that both the STS-PROM and EuroSCORE II were better calibrated in a more recent patient cohort (Table 4 , Fig. 4 ). Calibration improved for both the STS-PROM and EuroSCORE II in the overall cohort (O:E = 0.96 and 0.80, respectively), in isolated CABG (O:E = 0.99 and 0.73, respectively). Especially in low-risk, recent CABG patients both scores are well calibrated. The STS-PROM improved for low-risk AVR and AVR + CABG procedures ( Fig. 4C and D) . The small samples of patients who underwent MV repair or MV replacement resulted in disparate calibration results. Discrimination was similar across procedures, scores and time (Tables 2 and 4) .
DISCUSSION
This is the first study that validated EuroSCORE II in a large multicentre US database and compared its performance with the STS-PROM across a range of cardiac surgical procedures. Overall, the STS-PROM was better calibrated and was superior in discriminating patients who were likely to survive cardiac surgery from those who were more likely not to survive. Nevertheless, the performance of EuroSCORE II was satisfactory, especially in recent low-risk CABG and non-CABG procedures. In patients who underwent AVR, both STS-PROM and EuroSCORE II over-predicted Table 2 : Performance in the overall cohort and in different types of procedures [7] [8] [9] [10] [11] [12] [13] . Two of them compared the performance with the STS-PROM [7, 12] . Kirmani et al. [12] used data from more than 15 000 patients who underwent CABG, valve surgery or a combined procedure. They concluded that both models provide equivalent discrimination, and that calibration is good in patients with a predicted risk of mortality <15%. Differences with the current results are most likely caused by the different underlying patient population. The STS-PROM and its variables are routinely collected, scrutinized and calculated in the USA, whereas this is not the case in the majority of European centres.
ADULT CARDIAC
There are several reasons for the better performance of the STS-PROM compared with EuroSCORE II. First of all, the STS-PROM was created using datasets that were much larger than the development datasets of EuroSCORE II. The CABG model of STS-PROM version 2.61 was based on almost 500 000 patients, whereas the development cohort of EuroSCORE II comprised less than 8000 CABG patients [6, 21] . In addition, the EuroSCORE II data set contained data from 43 countries ranging from China to Sudan, whereas the STS-PROM database only comprises US centres. Moreover, the STS models used more elaborate statistical methods to deal with missing data. Taking these methodological considerations into account, the performance of EuroSCORE II is still satisfactory; the differences with the STS-PROM are relatively small and calibration is even largely similar in low-risk patients, which is the most common patient group in everyday clinical practice.
The current results support the importance of frequently updating risk scores. The sensitivity analysis of recent cases showed that the calibration of both models improved when applied to contemporary practice. Whereas the STS-PROM score is regularly updated, EuroSCORE II was essentially the first update after the additive and logistic versions that were based on data from 1995 [2, 3, 6] . The poor calibration of the original EuroSCORE has been reported elaborately and was confirmed again in this study [5] . The update makes EuroSCORE II better applicable to current practice. Operative techniques, patients and general clinical management change over time and have an impact on outcomes. These developments cannot be neglected when developing and applying risk models.
The advantage of EuroSCORE II is that it is easier to calculate. Whereas the STS-PROM contains more than 40 variables, EuroSCORE II requires only 18 variables [22] . Some studies even suggest that it could be further simplified by removing eight variables, without sacrificing performance [8] . A parsimonious model is more user-friendly, less resource-intensive and is more likely to be used in settings where risk scoring and collection of documentation of variables are not obligatory.
Implications for transcatheter aortic valve implantation
Risk models are a method of standardizing inclusion into trials across different study sites in different countries. Although not designed for TAVI, the STS-PROM and EuroSCORE are currently used in several studies that investigate TAVI in patients with severe AS. Two major ongoing multinational trials compare TAVI with surgical AVR in patients at intermediate operating risk: the Placement of AoRTic TraNscathetER Valve (PARTNER) 2 and Safety and Efficacy Study of the Medtronic CoreValve® System in the Barili et al. [7] compared EuroSCORE II with the STS-PROM in patients who underwent isolated AVR and found that it was associated with worse discrimination, but better calibration when compared with the STS-PROM. Both scores had a tendency of under-prediction in higher-risk patients in this data set of 1758 Italian patients, of which a small proportion was at high risk. In the total data set only 25 (1.4%) patients died, which makes inferences regarding discrimination and calibration in the small high-risk group less reliable. We found that EuroSCORE II over-predicts mortality in intermediate-and high-risk patients, and that its calibration is similar to the STS-PROM (O:E = 0.74 in intermediate-and 0.51 in high-risk patients).
If solely selected on the basis of these scores, patients are in fact at lower risk than anticipated. The mean STS-PROM in cohort A of the PARTNER trial was 12, which corresponds to an actual mortality rate of 8.5% (O:E = 0.71 in high-risk patients) [25] . TAVI trials aimed at patients with an estimated 4-10% risk of mortality are actually enrolling patients with mean estimated risks of 6.0% (STS-PROM) or 6.2% (EuroSCORE II). Relying exclusively on risk scores may introduce bias in the interpretation of the study results due to model limitations. While underestimation leads to more conservative patient selection, overestimation leads to potentially recruiting patients for an investigational therapy, while they might be better off with conventional AVRs with well-established efficacy and long-term results.
Also in everyday clinical practice, decision-making should not be based solely on risk scores. There are several factors that are not included in the risk scores, but might be very important for outcomes: frailty, vessel tortuosity, porcelain aorta, chest wall malformation or chest radiation. Recently, gait speed was added to the updated STS-PROM as a proxy for frailty. New risk models that incorporate these variables are being developed, but need to be validated [23] .
A multidisciplinary heart team approach is essential to combine risk scores, clinical judgement and these additional aspects. Over the past years, multidisciplinary decision-making has gained more attention in the cardiovascular community. The team includes a cardiac surgeon, interventional cardiologist, clinical cardiologist, nurse practitioner and specialists in imaging, heart failure and cardiac rehabilitation. Physicians have become accustomed to this approach and it is recommended to select the optimal treatment strategy for patients with aortic stenosis, both in everyday practice and in clinical trials [23] .
Implications for outcome comparisons across centres
There is an increasing interest in comparative clinical outcome analyses and performance in high-risk (cardiac) surgery is likely to be an important quality indicator. These analyses require robust models to adjust for case-mix. However, our study shows that using the STS-PROM or EuroSCORE II in certain patient groups is inappropriate because of inadequate calibration. While the excellent calibration of the STS-PROM in recent CABG surgery allows for robust risk-adjustment, the limited performance in other procedures should be taken into account when comparing outcomes across centres. More specifically, comparison of outcomes in high-risk patients is troublesome due to common miscalibration in these patients [13] .
Limitations
Definitions were based on the STS database, and for EuroSCORE II, some assumptions based on clinical judgement and combinations of other variables had to be made. Prospective studies collecting all variables exactly according to their EuroSCORE II definitions are needed to overcome this limitation. Also, the STS-PROM was calculated at the time of data entry, whereas EuroSCORE II was calculated retrospectively. Therefore, we cannot rule out that the performance of EuroSCORE II is an underestimation. Comparability with other validation studies of EuroSCORE II is not hampered, since they also had a retrospective nature and applied similar assumptions. Although we performed sensitivity analyses based on risk and mortality profiles over time, there is the possibility of dynamic changes in case-mix and risk factors influencing the results [17, 18] .
Another limitation is that risk models and the current manuscript focus on short-term mortality. Although the optimal timeframe for the mortality outcome is contentious, a validation study like ours should use the same outcome measure as the development study.
CONCLUSION
In a large US multicentre database, the STS-PROM performs better than EuroSCORE II for CABG. However, EuroSCORE II is a reasonable alternative in recent low-risk CABG patients and in those undergoing other cardiac surgical procedures. For AVRs, both models over-predict mortality. Clinical trials and physicians using these scores recruit patients who are at a lower risk than anticipated, potentially leading to overtreatment with an investigational device. Decision-making should not solely be based on risk scores, but should comprise multidisciplinary heart team discussions.
APPENDIX. CONFERENCE DISCUSSION
Dr W.T. Brinkman (Dallas, TX, USA): The authors are to be complimented on the arduous task of trying to go through and reconcile these two disparate risk models.
As you point out, the STS-predicted risk mortality is based on 500,000 patients, while the EuroSCORE II is 23,000 patients. In the STS-predicted risk, the mortality contains one of the 40 variables, while in the EuroSCORE it is 18. And in fact, the STS database is soon going to expand to include more variables to take into account important factors such as cirrhosis, calcification of the aorta, things like that.
So proper risk stratification is critical with the advent of new disruptive technologies such as TAVR. Currently, the FDA in the United States limits the application of TAVR to non-operative and high-risk patients. To broaden the use of TAVR in the US, clear risk stratification is mandatory. Trials such as SURTAVI and PARTNER II were designed with these questions in mind, as you brought up. So in the light of all that, I have some questions.
My first question. When calculating your STS risk score, if the New York Heart Association classification was absent, you assumed it was Class I. That seemed to me to be an important factor in a patient with a valve disease. So what was the absent rate in valve patients where you were just assuming Class I? And might that be a problem for calculating the STS risk, seeing how the New York Heart Association is a strong variable in the STS calculation? Dr Osnabrugge: What we did with the NYHA class is important. When you calculate the STS score online and you click on "Congestive Heart Failure," you'll get a pop-up box where you can fill in the NYHA class. If you say okay, there is no congestive heart failure, then you don't get that box, and that's why we felt comfortable to say it was absent in those cases.
For the specific AVR subgroup, I don't know the absent rate exactly for this subgroup. I would have to go back to the data. But, in line with my first answer, I think we felt comfortable to assume Class I when NYHA was missing.
Dr Brinkman: Okay. My next question. Your data does support the STS for being superior in performance of all procedures and CABG, and your data was 80% CABG. So, with only 7% of AVR in your study group and a non-significant difference between the AUC comparisons between the STS and the EuroSCORE, do you really think that proves that EuroSCORE II is a reasonable alternative to the STS, and is there enough power to really make that statement?
Dr Osnabrugge: Well, of course, we would like to have more patients, but I think this is the largest AVR group in which the STS score and the EuroSCORE II have been compared. So I think it's the best data there is. And, yes, of course, even more patients would have been better.
Dr Brinkman: Okay. One final question. In our cardiac surgery clinic in Dallas, on a daily basis, we calculate the STS for all our patients. It is required for a lot of reasons, and especially for inclusion in trials such as PARTNER II and SURTAVI, and it is not a big deal for us to go and use the online tool. It takes us just a few minutes. We don't use the EuroSCORE. Could you tell me why we should be calculating the EuroSCORE?
Dr Osnabrugge: Well, that's a great question. Less is more, maybe. The EuroSCORE II only has 18 variables. And if the performance is similar, I think it would be a good idea to also calculate the EuroSCORE II. But more importantly, it is also nice to have the EuroSCORE II to compare your patients to patients who are included in studies in Europe. It results in a better comparison when you look across the Atlantic.
Dr D. Pagano (Birmingham, U.K.): I have a comment and a question for you. The comment is that it is quite clear now that we have a paradox. If you look at the isolated, first-time coronary artery bypass grafting, the mortality is so low for in-hospital mortality or short-term outcome, that you almost don't need risk stratification consistently for mortality.
The question is about the high-risk group. There is a common thread here. The groups in which it is very important to make a clinical decision, particularly when there are alternatives, are the groups in which the risk algorithms perform badly. Have you got an idea why that may be the case, and how would you improve that?
Dr Osnabrugge: The question is, why in the high-risk patients are the scores performing badly? There are always fewer patients in this higher-risk category, so the estimates become unstable. It is unfortunate, but we have less data on these patients.
Dr Pagano: Can I have the opportunity of asking Fred what he thinks about this issue, because it is a fundamental issue? Dr F.H. Edwards (Chicago, IL, USA): First of all, I think it is a great question, and I agree with your answer. Yes, you've got smaller numbers once you get up into that higher spectrum. For years at STS we've talked about just accumulating those high-risk patients and making a separate risk model devoted specifically to those higher-risk patients. And over the years, we would have enough numbers, I think, to be able to obviate the problem that you point out. So we're going to try to do that. In the meantime, I think we're just left with exactly the situation that you describe and, again, I think your answer to it is perfect. Dr J. Gummert (Bad Oeynhausen, Germany): One more question. Could you speculate, if you were to make the same analysis in European patients comparing EuroSCORE II and STS score, could it be possible that the difference you've seen reflects maybe differences in the different healthcare systems, in terms of indication, in terms of treatment policies?
Dr Osnabrugge: It is difficult to really pinpoint that that would be the reason. There has been, off the top of my head, one other study which looked at this. They got similar results with slightly fewer patients. That was a European data set, and the overall conclusion was similar.
Dr N. Van Mieghem (Rotterdam, Netherlands): First of all, I wanted to mention when you determined the STS score and you didn't know the New York Heart Association class, if it was I, II, or III, does that not change the score? That is to begin with. And then the other thing is, it is very difficult to compare risk models if you do not use the same definitions. For instance, peripheral arterial disease is defined differently in EuroSCORE and STS. So did you take that into account?
Dr Osnabrugge: It is difficult, and that is definitely a limitation of this comparison. That is the only thing I can say about it. And with regard to the first question on NYHA class, this is more of a problem if you want to calculate the EuroSCORE II and you have to include the NYHA class there, that is where the problem arises. Not in the STS score, because it is included there sort of automatically.
